Rani raises cash for 'holy grail' of oral formulations for biologics

Rani Therapeutics completed a Series B funding round to finance technology that's designed to convert biologics into pills, which could give pharmaceutical companies a competitive advantage and extend the patent lives of blockbuster injectable drugs, according to the company's chairman and CEO Mir Imran.